First patients receive experimental 'Living Drug' for tough cancers
NCT ID NCT05120271
Summary
This is a first-in-human study to test the safety and find the right dose of a new cell therapy called BOXR1030. It is for adults with advanced solid tumors (like certain liver, lung, skin, and soft tissue cancers) that have a specific protein marker called GPC3. Doctors will collect a patient's own immune cells, modify them in a lab to target the cancer, and then infuse them back after a short course of chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor Scott and White Research Institute
Dallas, Texas, 75246, United States
-
Beatson Institute for Cancer Research Wolfson Wohl Cancer Research Centre
Glasgow, G61 1BD, United Kingdom
-
Fred Hutchinson Cancer Center - Seattle Cancer Care Alliance (SCCA) Location
Seattle, Washington, 98109, United States
-
Froedtert and Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Hoag Hospital Newport Beach
Newport Beach, California, 92663, United States
-
The Royal Marsden NHS Foundation Trust
London, SW3 6JJ, United Kingdom
-
University College London Hospitals NHS Foundation Trust
London, NW1 2PG, United Kingdom
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030-4008, United States
Conditions
Explore the condition pages connected to this study.